Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 1
2004 3
2005 2
2007 4
2008 3
2009 1
2010 2
2011 2
2012 4
2013 3
2014 4
2015 2
2016 11
2017 7
2018 7
2019 5
2020 10
2021 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Cited In for PMID: 10706647

75 results

Results by year

Filters applied: . Clear all
Page 1
Second-line treatment of ovarian cancer.
Markman M, Bookman MA. Markman M, et al. Oncologist. 2000;5(1):26-35. doi: 10.1634/theoncologist.5-1-26. Oncologist. 2000. PMID: 10706647 Free article. Review.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Santin AD, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland LJ, Monk BJ, Coleman RL, Herzog TJ, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter AO, Childs BH, Elbi C, Bulat I. Santin AD, et al. Int J Gynecol Cancer. 2023 Apr 3;33(4):562-570. doi: 10.1136/ijgc-2022-003927. Int J Gynecol Cancer. 2023. PMID: 36564099 Free PMC article. Clinical Trial.
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.
Sassu CM, Palaia I, Boccia SM, Caruso G, Perniola G, Tomao F, Di Donato V, Musella A, Muzii L. Sassu CM, et al. Int J Mol Sci. 2021 Dec 20;22(24):13650. doi: 10.3390/ijms222413650. Int J Mol Sci. 2021. PMID: 34948446 Free PMC article. Review.
Pharmacological Inhibition of BAD Ser99 Phosphorylation Enhances the Efficacy of Cisplatin in Ovarian Cancer by Inhibition of Cancer Stem Cell-like Behavior.
Wang Y, Chiou YS, Chong QY, Zhang M, Rangappa KS, Ma L, Zhu T, Kumar AP, Huang RY, Pandey V, Basappa, Lobie PE. Wang Y, et al. ACS Pharmacol Transl Sci. 2020 Oct 9;3(6):1083-1099. doi: 10.1021/acsptsci.0c00064. eCollection 2020 Dec 11. ACS Pharmacol Transl Sci. 2020. PMID: 33344891 Free PMC article.
75 results